CHGA and neoplasm: Chromogranin A (CgA) has been used as a valuable tumor marker in NETs, and elevated levels of both CgA and 5-hydroxyindoleacetic acid (5-HIAA) have previously been associated with poor prognosis in these patients [18,29].